Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
View/ Open
Author
de Wit, Djoeke
van Erp, Nielka P
Khosravan, Reza
Wiltshire, Robin
Allred, Randy
Guchelaar, Henk-Jan
Gelderblom, Hans
Published Version
https://doi.org/10.1186/1471-2407-14-575Metadata
Show full item recordCitation
de Wit, Djoeke, Nielka P van Erp, Reza Khosravan, Robin Wiltshire, Randy Allred, George D Demetri, Henk-Jan Guchelaar, and Hans Gelderblom. 2014. “Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.” BMC Cancer 14 (1): 575. doi:10.1186/1471-2407-14-575. http://dx.doi.org/10.1186/1471-2407-14-575.Abstract
Background: GIST patients often undergo GI-surgery. Previous studies have shown that imatinib and nilotinib exposures were decreased in GIST patients with prior major gastrectomy. We investigated whether major gastrectomy influences the exposure to sunitinib and its active metabolite SU12662. Methods: Pharmacokinetic data from 305 GIST patients included in 4 phase I-III trials were analyzed. Patients were subdivided into 6 groups according to their prior GI-surgery. Apparent clearance (CL/F) and dose-corrected steady-state plasma exposures (AUC24,ss) of sunitinib and SU12662 were estimated using a population PK approach. ANCOVA was performed to test for differences in AUC24,ss and CL/F between each surgery subgroup and controls. Results: Major gastrectomy did not influence sunitinib or SU12662 exposure. The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng*hr/mL (95%-CI; 676–1283) versus 1177 ng*hr/mL (95%-CI; 1097–1263); p < 0.05) and SU12662 (354 ng*hr/mL (95%-CI; 174–720) versus 492 ng*hr/mL (95%-CI; 435–555); p < 0.05). No significant differences in exposure were observed in each of the other subgroups versus controls. Conclusion: In contrast to previous results for imatinib and nilotinib, gastrectomy alone does not influence sunitinib or SU12662 exposure. This should be taken into account for the treatment of gastrectomized GIST patients with TKIs. In patients who had undergone both gastrectomy and small bowel resection, sunitinib and SU12662 exposures are significantly, although clinically not relevantly, decreased.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133599/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785893
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)